<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893357</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-Fatim</org_study_id>
    <nct_id>NCT03893357</nct_id>
  </id_info>
  <brief_title>Prevalence of Antiphospholipid Antibodies in the Hemodialysis Patients Population Within the CHU Brugmann Hospital</brief_title>
  <official_title>Retrospective Study of the Prevalence of Antiphospholipid Antibodies in the Population of Hemodialysis Patients at the CHU Brugmann Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with a chronic renal disease at the terminal stage, extrarenal epuration is
      essential for the control of clinico-biological complications. Two extrarenal epuration
      techniques are currently available: peritoneal dialysis (using the peritoneal membrane of the
      patient) and hemodialysis, requiring the use of an external biocompatible membrane known as
      'dialysis filter'. This technique requires a vascular access (arteriovenous fistula or
      dialysis catheter). The thrombosis of vascular accesses represents a major cause of morbidity
      and mortality in hemodialysis patients. Thrombosis are more frequent when using synthetic
      prosthetic arteriovenous fistula instead of native arteriovenous fistula.

      Antiphospholipid Syndrome (APLS) is a rare autoimmune disease characterized by arterial
      thrombosis, venous thrombosis and obstetrical complications such as as defined by the
      Sidney's criteria.

      In the general population, the presence of antiphospholipid antibodies is associated with an
      increased risk of thromboembolic events. In the nephrological population, this prevalence is
      higher in hemodialysis patients compared to patients on peritoneal dialysis or non-dialyzed
      patients. Up to 37% of hemodialysis patients are positive for antiphospholipid antibodies and
      this biology is associated with thrombotic events and vascular access thromboses. However,
      some studies do not report this association and there is currently no consensus in terms of
      the therapeutic management of these patients.

      Some factors influencing the positivity for antiphospholipid antibodies have been reported:
      smoking, age, the presence of a non-glomerular nephropathy, hypoalbuminaemia, the use of a
      central venous catheter for dialysis or the use of a non-biocompatible dialysis membrane.

      Taking into account the conflicting data from the literature, it seems important to study the
      respective role(s) of 3 types of antiphospholipid antibodies in the occurrence of thrombo-
      embolic events in patients undergoing dialysis within the CHU Brugmann Hospital.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">July 25, 2019</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of antiphospholipid antibodies</measure>
    <time_frame>19 years</time_frame>
    <description>Prevalence of antiphospholipid antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of arterial thrombosis</measure>
    <time_frame>19 years</time_frame>
    <description>Prevalence of arterial thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of venous thrombosis</measure>
    <time_frame>19 years</time_frame>
    <description>Prevalence of venous thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maturation delay of the arteriovenous fistula</measure>
    <time_frame>19 years</time_frame>
    <description>Maturation delay of the arteriovenous fistula</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of thrombosis of the filter</measure>
    <time_frame>19 years</time_frame>
    <description>Percentage of thrombosis of the filter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lifespan of the catheter</measure>
    <time_frame>19 years</time_frame>
    <description>Lifespan of the catheter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lifespan of the fistula</measure>
    <time_frame>19 years</time_frame>
    <description>Lifespan of the fistula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Existence of thrombosis risk factors</measure>
    <time_frame>19 years</time_frame>
    <description>Existence of at least one of the following pro-thrombotic risk factors: smoking, active neoplasia, arterial hypertension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulant treatment</measure>
    <time_frame>19 years</time_frame>
    <description>Existence of an anticoagulant treatment
Presence of an anticoagulant treatment by means of anti-vitamin K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet treatment Antiplatelet treatment</measure>
    <time_frame>19 years</time_frame>
    <description>Existence of an antiplatelet treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive treatment</measure>
    <time_frame>19 years</time_frame>
    <description>Existence of an antihypertensive treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statin treatment</measure>
    <time_frame>19 years</time_frame>
    <description>Existence of a treatment by means of statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethiology of the nephropathy (known/unknown)</measure>
    <time_frame>19 years</time_frame>
    <description>Known versus unknown ethiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethiology of the nephropathy (glomerular)</measure>
    <time_frame>19 years</time_frame>
    <description>Glomerular versus non-glomerular ethiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at dialysis entry</measure>
    <time_frame>19 years</time_frame>
    <description>Age at dialysis entry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular access</measure>
    <time_frame>19 years</time_frame>
    <description>Catheter versus distal arteriovenous fistula versus proximal arteriovenous fistula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of dialysis</measure>
    <time_frame>19 years</time_frame>
    <description>Hemodiafiltration versus conventional hemodialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of per-dialytic anticoagulation</measure>
    <time_frame>19 years</time_frame>
    <description>With or without heparin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brand of dialysis membrane</measure>
    <time_frame>19 years</time_frame>
    <description>Brand of dialysis membrane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea change percentage</measure>
    <time_frame>Last available result within 19 years</time_frame>
    <description>Urea change percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Last available result within 19 years</time_frame>
    <description>Coagulation assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin count</measure>
    <time_frame>Last available result within 19 years</time_frame>
    <description>Hemoglobin count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets count</measure>
    <time_frame>Last available result within 19 years</time_frame>
    <description>Platelets count</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Positive for antiphospholipid antibodies</arm_group_label>
    <description>Patients tested positive for antiphospholipid antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative for antiphospholipid antibodies</arm_group_label>
    <description>Patients tested negative for antiphospholipid antibodies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data extraction from medical files</intervention_name>
    <description>Retrospective data extraction from the medical files</description>
    <arm_group_label>Negative for antiphospholipid antibodies</arm_group_label>
    <arm_group_label>Positive for antiphospholipid antibodies</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing dialysis within the CHU Brugmann Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All patients undergoing dialysis within the CHU Brugmann Hospital

        Exclusion Criteria:

          -  Mutation of factor V

          -  Mutation G20210A of the prothrombin gene

          -  Protein C deficiency

          -  Protein S deficiency

          -  Antithrombin III deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camara Fatim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Agnieszka Pozdzik</investigator_full_name>
    <investigator_title>Head of clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

